SleepHub device to be assessed in people with Parkinson’s associated sleep issues
News
Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant
Vaccine found to have an overall vaccine efficacy of 89.7% in Phase III trial
AZ’s vaccine safety review shows ‘no evidence’ of an increased risk of blood clots
Review included available safety data from over 17 million people vaccinated in the EU and UK with COVID-19 jab
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Phase III trial stopped early for positive result on overall survival
New real-world evidence for Pfizer/BioNTech COVID-19 vaccine
Evidence demonstrates lower incidence rates of COVID-19 in fully vaccinated individuals
NHS England breast cancer wait times are ‘deeply worrying’
All waiting time targets for breast cancer were missed in January
EU approval for J&J’s single-shot COVID-19 vaccine
Conditional marketing authorisation closely follows positive opinion from CHMP
NHS Staff Survey shows ‘profound impact’ of COVID-19 pandemic on workforce
Raises concerns over wellbeing of staff working during pandemic
DNA production specialist Touchlight raises £42m
Proceeds will be used to ‘more than triple’ UK biotech’s manufacturing capabilities
GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage
British drugmaker to expand its clinical manufacturing capacity for cell and gene therapy
Researchers identify inflammatory protein associated with severe COVID-19
Cytokine GM-CSF found at higher levels in people who progressed to severe COVID-19
Pharma, comms and patient group leaders join judging panel for Patient Partnership Index 2021
Senior leaders from UK and European pharma have come together to judge the Patient Partnership Index 2021
MHRA authorises Lilly’s RET inhibitor Retsevmo
Oral therapy approved for RET-driven advanced lung and thyroid cancers
Roche withdraws US indication for Tecentriq in bladder cancer
Tecentriq failed to improve overall survival in post-marketing study
MHRA green light for DemeRx’s opioid use disorder trial
Phase I portion of the trial will be conducted at the Manchester clinical unit of MAC Clinical Research
